Amgen Inc.'s denosumab - already under FDA review for bone loss - generated better-than-expected data in its first Phase III oncology trial, boosting confidence in ongoing studies and enhancing the drug's potential to offset Amgen's flagging core franchises. (BioWorld Today) Read More
